Fig. 1From: Clinical significance of high monocyte counts for the continuous treatment with nintedanibDecline in forced vital capacity (FVC) within one year by starting dosage. The average annual FVC reduction by starting dosage is shown. The reduced starting dosage group had an FVC reduction of − 91.6 mL (− 266–+42.8), and the normal starting dosage group had a reduction of − 177.6 mL (− 254–+101). No significant difference was found (P = 0.1361)Back to article page